Bisphosphonates: From bench to bedside

Annals of the New York Academy of Sciences

Volumn 1068, Issue 1, 2006, Pages 367-401

  Russell, R Graham G ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Bisphosphonates; Bone metastases; Bone resorption; Myeloma; Osteoclasts; Osteoporosis; Protein prenylation

Indexed keywords

ADENOSINE TRIPHOSPHATE; ALENDRONIC ACID; ANTINEOPLASTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; CORTICOSTEROID; EB 1053; ETIDRONIC ACID; GLUCOCORTICOID; GUANINE NUCLEOTIDE BINDING PROTEIN; GUANOSINE TRIPHOSPHATASE; HEPARIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IBANDRONIC ACID; INCADRONIC ACID; ISOPRENOID; MEVALONIC ACID; MINODRONIC ACID; NERIDRONIC ACID; NITROGEN; OLPADRONIC ACID; PAMIDRONIC ACID; PARATHYROID HORMONE[1-34]; PHOSPHONOCARBOXYLATE; PHOSPHONOPHOSPHINATE; PYROPHOSPHATE; RISEDRONIC ACID; TECHNETIUM; TILUDRONIC ACID; UNCLASSIFIED DRUG; ZOLEDRONIC ACID;

ALBERS SCHOENBERG DISEASE; APOPTOSIS; BIOSYNTHESIS; BONE ATROPHY; BONE DESTRUCTION; BONE DISEASE; BONE METASTASIS; BONE MINERAL; BONE NECROSIS; CALCIFICATION; CELL ACTIVITY; CLINICAL TRIAL; CONFERENCE PAPER; CRYSTAL STRUCTURE; DENTAL CARIES; DOSE RESPONSE; DRUG ABSORPTION; DRUG BINDING; DRUG DEGRADATION; DRUG DESIGN; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HYDROLYSIS; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG POTENCY; DRUG POTENTIATION; DRUG STABILITY; DRUG UPTAKE; ENZYME INHIBITION; FEVER; FLU LIKE SYNDROME; GASTROINTESTINAL SYMPTOM; HETEROTOPIC OSSIFICATION; HUMAN; HYPERCALCEMIA; JAW DISEASE; LOW DRUG DOSE; MYELOMA; NONHUMAN; OSSIFYING MYOSITIS; OSTEOCLAST; OSTEOGENESIS IMPERFECTA; OSTEOLYSIS; OSTEOPOROSIS; PAGET BONE DISEASE; PATHOGENESIS; PATHOLOGIC FRACTURE; PRENYLATION; PROTEIN FUNCTION; PROTEIN PROCESSING; SCINTISCANNING; SPINAL CORD COMPRESSION; SPINE FRACTURE; STRUCTURE ACTIVITY RELATION; TOOTH CALCULUS; UNSPECIFIED SIDE EFFECT;

EID: 33744762777     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1196/annals.1346.041     Document Type: Conference Paper

References (214)

1. Menschutkin, N. 1865. Ueber die Einwirkung des Chloracetyls auf phosphorige Saure. Ann. Chem. Pharm. 133 : 317 320.
2. Smith, R., R.G.G. Russell & M. Bishop. 1971. Diphosphonates and Paget's disease of bone. Lancet 1 : 945 947.
3. Von Baeyer, H. & K.A. Hofmann. 1897. Acetodiphosphorige Saure. Berichte Dtsch. Chem. Ges. 20 : 1973 1978.
4. Blomen, L.J.M.J. 1995. Discovery and history of the non-medical uses of bisphosphonates. Chapter 7. In Bisphosphonates on Bone. O. Bijvoet, et al. Eds 111 124. Elsevier Science B.V. Amsterdam.
5. Russell, R.G. & M.J. Rogers. 1999. Bisphosphonates: from the laboratory to the clinic and back again [review]. Bone 25 : 97 106.
6. Bijvoet, O., H. Fleisch, R.E. Canfield & R.G.G. Russell, Eds. 1995. Bisphosphonates on Bone. Elsevier Science B.V. Amsterdam.
7. Fleisch, H. 2000. Bisphosphonates in Bone Disease. From the Laboratory to the Patient, 4th ed. Academic Press. New York.
8. Fleisch, H. 1998. Bisphosphonates: mechanisms of action. Endocr. Rev. 19 : 80 100.
9. Ebetino, F.H., M.D. Francis, M.J. Rogers, et al. 1998. Etidronate. Mechanisms of action of etidronate and other bisphosphonates. Revs. Contemp. Pharma 9 : 233 243.
10. Green, J.R. 2004. Bisphosphonates: preclinical review. Oncologist. 9 Suppl 4 3 13.
11. Russell, R.G.G. & M.J. Rogers. 1997. Introduction to bisphosphonates and the clinical pharmacology of alendronate. Br. J. Rheumatol. 36 S 10 14.
12. Johnson, S. & F.N. Johnson, Eds. 1998. Etidronate in Osteoporosis, Vol 9. Rev in Contemp Pharm. Marius Press. Lancashire, UK.
13. Geddes, A.D., S.M. D'Souza, F.H. Ebetino, et al. 1994. Bisphosphonates: structure-activity relationships and therapeutic implications. Bone Miner. Res. 8 : 265 306.
14. Sietsema, W.K., F.H. Ebetino, A.M. Salvagno, et al. 1989. Antiresorptive dose-response relationships across three generations of bisphosphonates. Drugs Exp. Clin. Res. 15 : 389 396.
15. Rogers, M.J. 2004. From molds and macrophages to mevalonate: a decade of progress in understanding the molecular mode of action of bisphosphonates [review]. Calcif. Tissue Int. 75 : 451 461.
16. Papapoulos, S.E. 1995. Pharmacodynamics of bisphosphonates in man. Chapter 15. In Bisphosphonates on Bone. O. Bijvoet, et al. Eds Elsevier Science B.V. Amsterdam.
17. Rondeau, J.M., F. Bitsch, E. Boirgier, et al. 2006. Structural basis for the exceptional in vivo efficacy of bisphosphonate drugs. Chem. Med. Chem. 1 : 267 273.
18. Michaelson, M.D. & M.R. Smith. 2005 Bisphosphonates for treatment and prevention of bone metastases [review]. J. Clin. Oncol. 23 : 8219 8224.
19. Fleisch, H. & W.F. Neuman. 1961. Mechanisms of calcification: role of collagen, polyphosphates, and phosphatase. Am. J. Physiol. 200 : 1296 1300.
20. Fleisch, H. & S. Bisaz. 1962. Isolation from urine of pyrophosphate, a calcification inhibitor. Am. J. Physiol. 203 : 671 675.
21. Fleisch, H., R.G.G. Russell & F. Straumann. 1966. Effect of pyrophosphate on hydroxyapatite and its implications in calcium homeostasis. Nature 212 : 901 903.
22. Russell, R.G.G. & A. Hodgkinson. 1966. The urinary excretion of inorganic pyrophosphate by normal subjects and patients with renal calculus. Clin. Sci. 31 : 51 62.
23. Russell, R.G.G. 1965. Excretion of inorganic pyrophosphate in hypophosphatasia. Lancet 10 : 461 464.
24. Russell, R.G.G., S. Bisaz, A. Donath, et al. 1971. Inorganic pyrophosphate in plasma in normal persons and in patients with hypophosphatasia, osteogenesis imperfecta and other disorders of bone. J. Clin. Invest. 50 : 961 969.
25. Schibler, D., R.G.G. Russell & H. Fleisch. 1968. Inhibition by pyrophosphate of aortic calcification induced by Vitamin D3 in rats. Clin. Sci. 35 : 363 372.
26. Fleisch, H., R.G.G. Russell, S. Bisaz, et al. 1968. The influence of pyrophosphate analogues (diphosphonates) on the precipitation and dissolution of calcium phosphate in vitro and in vivo. Calcif. Tissue Res. 2 : 10 10A.
27. Francis, M.D., R.G.G. Russell & H. Fleisch. 1969. Diphosphonates inhibit formation of calcium phosphate crystals in vitro and pathological calcification in vivo. Science 165 : 1264 1266.
28. Fleisch, H., R.G.G. Russell & M.D. Francis. 1969. Diphosphonates inhibit hydroxyapatite dissolution in vitro and bone resorption in tissue culture and in vivo. Science 165 : 1262 1264.
29. Jung, A., S. Bisaz & H. Fleisch. 1973. The binding of pyrophosphate and two diphosphonates by hydroxyapatite crystals. Calcif. Tissue Res. 11 : 269 280.
30. Fleisch, H.A., R.G.G. Russell, S. Bisaz, et al. 1970. The inhibitory effect of phosphonates on the formation of calcium phosphate crystals in vitro and on aortic and kidney calcification in vivo. Eur. J. Clin. Invest. 1 : 12 18.
31. Schenk, R., W.A. Merz, R. Muehlbauer, et al. 1973. Effect of ethane-1-hydroxy-1,1-diphosphonate (EHDP) and dichloromethylene diphosphonate (Cl2MDP) on the calcification and resorption of cartilage and bone in the tibial epiphysis and metaphysis of rats. Calcif. Tissue Res. 11 : 196 214.
32. Fleisch, H., J. Maerki & R.G.G. Russell. 1966. Effect of pyrophosphate on dissolution of hydroxyapatite and its possible importance in calcium homeostasis. Proc. Soc. Exp. Biol. 122 : 317 320.
33. Russell, R.G.G., R.C. Muhlbauer, S. Bisaz, et al. 1970. The influence of pyrophosphate, condensed phosphates, phosphonates and other phosphate compounds on the dissolution of hydroxyapatite in vitro and on bone resorption induced by parathyroid hormone in tissue culture and in thyroparathyroidectomised rats. Calcif. Tissue Res. 6 : 183 196.
34. Trechsel, U., A. Stutzer & H. Fleisch. 1987. Hypercalcaemia induced with an arotinoid in thyroparathyroidectomised rats. A new model to study bone resorption in vivo. J. Clin. Invest. 80 : 1679 1686.
35. Stutzer, A., H. Fleisch & U. Trechsel. 1988. Short and long term effects of a single dose of bisphosphonates on retinoid-induced bone resorption in thyroparathyroidectomised rats. Calcif. Tissue Int. 43 : 294 299.
36. Schenk, R., P. Eggli, H. Fleisch, et al. 1986. Quantitative morphometric evaluation of the inhibitory activity of new aminobisphosphonates on bone resorption in the rat. Calcif. Tiss. Int. 38 : 342 349.
37. Gasser, A.B., D.B. Morgan, H.A. Fleisch, et al. 1972. The influence of two diphosphonates on calcium metabolism in the rat. Clin. Sci. 43 : 31 45.
38. Muehlbauer, R.C., R.G.G. Russell, D.A. Williams, et al. 1971. The effects of diphosphonates, polyphosphates and calcitonin on "immobilisation osteoporosis" in rats. Eur. J. Clin. Invest. 1 : 336 344.
39. Ferretti, J.L. 1995. Effects of bisphosphonates on bone biomechanics. Chapter 31. In Bisphosphonates on Bone. O. Bijvoet, et al. Eds Elsevier Science B.V. Amsterdam.
40. Shinoda, H., G. Adamek & R. Felix, et al. 1983. Structure-activity relationships of various bisphosphonates. Calcif. Tissue Int. 35 : 87 99.
41. Flanagan, A.M. & T.J. Chambers. 1989. Dichloromethylenebisphosphonate (Cl2MBP) inhibits bone resorption through injury to osteoclasts that resorb Cl2MBP-coated bone. Bone Miner. 6 : 33 43.
42. Reitsma, P.H., O.L.M. Bijvoet, H. Verlinden-Ooms, et al. 1980. Kinetic studies of bone and mineral metabolism during treatment with (3-amino-1-hydroxy-propylidene)-1,1-bisphosphonate (APD) in rats. Calcif. Tissue Int. 32 : 145 157.
43. Garnero, P., W.J. Shih, E. Gineyts, et al. 1994. Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment. J. Clin. Endocrinol. Metab. 79 : 1693 1700.
44. Bauss, F. & R.G.G. Russell. 2004. Ibandronate in osteoporosis: preclinical data and rationale for intermittent dosing. Osteoporos. Int. 15 : 423 433.
45. Gasser, J.A. & J.R. Green. 2002. Long-term protective effect of a single IV injection of zoledronic acid on cancellous bone structure and cortical bone in ovariectomized rats. Bone. 30 Suppl. 41S.
46. Ebrahimpour, A. & M.D. Francis. 1995. Bisphosphonate therapy in acute and chronic bone loss: physical chemical considerations in bisphosphonate- related therapies. In Bisphosphonate on bones. O. Bijvoet, et al. Eds Elsevier Science B.V Amsterdam.
47. Muehlbauer, R.C., F. Bauss, R. Schenk, et al. 1991. BM 21.0955, a potent new bisphosphonate to inhibit bone resorption. J. Bone Miner. Res. 6 : 1003 1011.
48. Papapoulos, S.E., K. Hoekman, C.W.G.M. Lowik, et al. 1988. Application of an in vitro model and a clinical protocol in the assessment of the potency of a new bisphosphonate. J. Bone Miner. Res. 4 : 775 781.
49. Goa, K.L. & J.A. Balfour. 1998. Risedronate. Drugs Aging 13 : 83 91.
50. Green, J.R., K. Mueller & K.A. Jaeggi. 1994. Preclinical pharmacology of CGP 42′446, a new, potent, heterocyclic bisphosphonate compound. J. Bone Miner. Res. 9 : 745 751.
51. Ebetino, F.H., A.V. Bayless, J. Amburgey, et al. 1996. Elucidation of a pharmacore for the bisphosphonate mechanism of bone antiresorptive activity. Phosphorus Sulfur Silicon Relat. Elem. 109/110 : 217 220.
52. van Beek, E., C. Lowik, I. Oue, et al. 1996. Dissociation of binding and antiresorptive properties of hydroxybisphosphonates by substitution of the hydroxyl with an amino group. J. Bone Miner. Res. 11 : 1492 1499.
53. Smith, R. 1995. Ectopic calcification and ossification. Chapter 31. In Bisphosphonate on Bones. O. Bijvoet, et al. Eds Elsevier Science B.V. Amsterdam.
54. Fogelman, I., R.G. Bessent, J.F. Turner, et al. 1978. The use of whole-body retention of Tc-99m diphosphonate in the diagnosis of metabolic bone disease. J. Nucl. Med. 19 : 270 275.
55. Francis, M.D. & I. Fogelman. 1987. 99mTc- diphosphonate uptake mechanisms on bone. In Bone Scanning in Clinical Practice. I. Fogelman, Ed 1 6. Springer Verlag. London.
56. Russell, R.G.G., R. Smith, C. Preston, et al. 1974. Diphosphonates in Paget's disease. Lancet 1 : 894 898.
57. Delmas, P.D. & P.J. Meunier. 1997. The management of Paget's disease of bone. N. Engl. J. Med. 336 : 558 566.
58. Daroszewska, A. & S.H. Ralston. 2005. Genetics of Paget's disease of bone. Clin. Sci. (Lond). 109 : 257 263.
59. Mee, A.P. 1999. Paramyxoviruses and Paget's disease: affirmative view. Bone 24 : 19S 21S.
60. Douglas, D.L., R.G.G. Russell, C.J. Preston, et al. 1980. Effect of dichloromethylene diphosphonate in Paget's disease of bone and in hypercalcaemia due to primary hyperparathyroidism or malignant disease. Lancet 1 : 1043 1047.
61. Coukell, A.J. & A. Markham. 1998. Pamidronate. A review of its use in the management of osteolytic bone metastases, tumour-induced hypercalcaemia and Paget's disease of bone. Drugs Aging 12 : 149 168.
62. Singer, F.R., T.L. Clemens & R.E. Eusebio. 1998. Risedronate, a highly effective oral agent in the treatment of patients with severe Paget's disease. J. Clin. Endocrinol Metab. 83 : 1906 1910.
63. Siris, E.S., A.A. Chines, R.D. Altman, et al. 1998. Risedronate in the treatment of Paget's disease of bone: an open label, multicenter study. J. Bone Miner. Res. 13 : 1032 1038.
64. Reid, I.R., P. Miller, K. Lyles, et al. 2005. Comparison of a single infusion of zoledronic acid with risedronate for Paget's disease. N. Engl. J. Med. 353 : 898 908.
65. Martodam, R.R., K.S. Thornton, D.A. Sica, et al. 1983. The effects of dichloromethylene diphosphonate on hypercalcemia and other parameters of the humoral hypercalcemia of malignancy in the rat Leydig cell tumor. Calcif. Tissue Int. 35 : 512 519.
66. Sasaki, A., B.F. Boyce, B. Story, et al. 1995. Bisphosphonate risedronate reduces metastatic human breast cancer burden in bone in nude mice. Cancer Res. 55 : 3551 3557.
67. Mundy, G.R. & T. Yoneda. 1995. Facilitation and suppression of bone metastasis. Clin. Orthop. Relat. Res. 312 : 34 44.
68. Mundy, G.R. 1998. Bisphosphonates as anticancer drugs. N. Engl. J. Med. 339 : 398 400.
69. Clezardin, P., F.H. Ebetino & P.G. Fournier. 2005. Bisphosphonates and cancer-induced bone disease: beyond their antiresorptive activity [review]. Cancer Res. 65 : 4971 4974.
70. Ross, J.R., Y. Saunders, P.M. Edmonds, et al. 2004. A systematic review of the role of bisphosphonates in metastatic disease [review]. Health Technol. Assess. 8 : 1 176.
71. Paterson, A.D., J.A. Kanis, E.C. Cameron, et al. 1983. The use of dichloromethylene diphosphonate for the management of hypercalcaemia in multiple myeloma. Br. J. Haematol. 54 : 121 131.
72. Ralston, S.H., S.J. Gallacher, U. Patel, et al. 1989. Comparison of three bisphosphonates in cancer-associated hypercalcaemia. Lancet ii : 1180 1182.
73. Body, J.J. 2004. Hypercalcemia of malignancy [review]. Semin. Nephrol. 24 : 48 54.
74. Sirohi, B. & R. Powles. 2004. Multiple myeloma [review]. Lancet 363 : 875 887.
75. Pavlakis, N., R. Schmidt & M. Stockler. 2005. Bisphosphonates for breast cancer. Cochrane Database Syst Rev. CD003474.
76. Coleman, R.E. 2005. Bisphosphonates in breast cancer [review]. Ann. Oncol. 16 : 687 695.
77. Parker, C.C. 2005. The role of bisphosphonates in the treatment of prostate cancer [review]. BJU Int. 95 : 935 938.
78. Smith, M.R. 2005. Zoledronic acid to prevent skeletal complications in cancer: corroborating the evidence. Cancer Treat. Rev. 31 Suppl 3 19 25.
79. Bell, R. 2005. Efficacy of ibandronate in metastatic bone disease: review of clinical data. Oncologist 10 Suppl 1 8 13.
80. Body, J.J., I.J. Diel, M. Lichinitzer, et al. 2004. Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo-controlled phase III studies. Br. J. Cancer 90 : 1133 1137.
81. McCloskey, E.V., I.C.M. MacLennan, M. Drayson, et al. 1998. A randomized trial of the effect of clodronate on skeletal morbidity in multiple myeloma. MRC working party on leukaemia in adults. Br. J. Haematol. 100 : 317 325.
82. Berenson, J.R., A. Lichtenstein, L. Porter, et al. 1996. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. N. Engl. J. of Med. 334 : 488 493.
83. Diel, I.J., E-F. Solomayer, S.D. Costa, et al. 1998. Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N. Engl. J. Med. 339 : 357 363.
84. Maerevoet, M., C. Martin & L. Duck. 2005. Osteonecrosis of the jaw and bisphosphonates. N. Engl. J. Med. 353 : 99 102.
85. 2004. Bone Health and Osteoporosis: A Report of the Surgeon General. U.S. Department of Health and Human Services, Office of the Surgeon General. Rockville, MD. http://www.surgeongeneral.gov/library.
86. Russell, R.G.G. 2003. Pathogenesis of osteoporosis. In Rheumatology, 3rd ed. M.C. Hochberg et al. Eds 2075 2147. publ. Mosby.
87. Watts, N.B., S.T. Harris, H.K. Genant, et al. 1990. Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. N. Engl. J. Med. 323 : 73 79.
88. Storm, T., G. Thamsborg, T. Steiniche, et al. 1990. Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis. N. Engl. J. Med. 322 : 1265 1271.
89. van Staa, T.P., L. Abenhain & C. Cooper. 1998. Use of cyclical etidronate and prevention of non-vertebral fractures. Br. J. Rheumatol. 37 : 87 94.
90. Liberman, U.A., S.R. Weiss, J. Broll, et al. 1995. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N. Engl. J. Med. 333 : 1437 1443.
91. Black, D.M., S.R. Cummings, D.B. Karpf, et al. 1996. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture intervention trial research group. Lancet 348 : 1535 1541.
92. Bone, H.G., D. Hosking, J.-P. Devogelaer, et al. for the Alendronate Phase III Osteoporosis Treatment Study Group. 2004. Ten years' experience with alendronate for osteoporosis in postmenopausal women. N. Engl. J. Med. 350 : 1189 1199.
93. Reginster, J., H.W. Minne, O.H. Sorensen, et al. 2000. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos. Int. 11 : 83 91.
94. McClung, M.R., P. Geusens, P.D. Miller, et al. and Hip Intervention Program Study Group. 2001. Effect of risedronate on the risk of hip fracture in elderly women. N. Engl. J. Med. 344 : 333 340.
95. Boonen, S., R.F. Laan, I.P. Barton, et al. 2005. Effect of osteoporosis treatments on risk of non-vertebral fractures: review and meta-analysis of intention-to-treat studies. Osteoporos. Int. 16 : 1291 1298.
96. Chavassieux, P.M., M.E. Arlot, C. Reda, et al. 1997. Histomorphometric assessment of the long term effects of alendronate on bone quality and remodeling in patients with osteoporosis. J. Clin. Invest. 100 : 1475 1480.
97. Adachi, J.D., W.G. Bensen, J. Brown, et al. 1997. Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis. N. Engl. J. Med. 337 : 381 387.
98. Saag, K.G., K. Emkey, T.J. Schnitzer, et al. 1998. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. N. Engl. J. Med. 339 : 292 229.
99. Glorieux, F.H., N.J. Bishop, H. Plotkin, et al. 1998. Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. N. Engl. J. Med. 33 : 947 952.
100. Rauch, F. & F.H. Glorieux. 2005. Osteogenesis imperfecta, current and future medical treatment. Am. J. Med. Genet. C. Semin. Med. Genet. 139 : 31 37.
101. Chesnut, C.H., A. Skag, C. Christiansen, et al. 2004. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J. Bone Miner. Res. 19 : 1241 1249.
102. Reid, I.R., J.P. Brown, P. Burckhardt, et al. 2002. Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N. Engl. J. Med. 346 : 653 661.
103. Adami, S. & N. Zamberlan. 1996. Adverse effects of bisphosphonates. Drug Saf. 14 : 158 170.
104. van Staa, T.P. 1998. Post marketing survey with ICT-etidronate therapy. Rev. Contemp. Pharm. 9 : 277 286.
105. DeGroen, P.C., D.F. Lubbe, L.J. Hirsch, et al. 1996. Esophagitis associated with the use of alendronate. N. Engl. J. Med. 355 : 1016 1021.
106. Hughes, D.E., B.R. MacDonald, R.G.G. Russell, et al. 1989. Inhibition of osteoclast-like cell formation by bisphosphonates in long-term cultures of human bone marrow. J. Clin. Invest. 83 : 1930 1935.
107. Boonekamp, P.M., L.J.A. van der Wee-Pals, M.L.L. van Wijk-van Lennep, et al. 1986. Two modes of action of bisphosphonates on osteoclastic resorption of mineralized matrix. Bone Miner. 1 : 27 39.
108. Löwik, C.W.G.M., G. van der Pluijm, L.J.A. van der Wee-Pals, et al. 1988. Migration and phenotypic transformation of osteoclast precursors into mature osteoclasts: the effect of a bisphosphonate. J. Bone Miner. Res. 3 : 185 192.
109. Suda, T., I. Nakamura, E. Jimi, et al. 1997. Regulation of osteoclast function. J. Bone Miner. Res. 12 : 869 879.
110. Masarachia, P., M. Weinreb, R. Balena, et al. 1996. Comparison of the distribution of 3H-alendronate and 3H-etidronate in rat and mouse bones. Bone 19 : 281 290.
111. Azuma, Y., H. Sato, Y. Oue, et al. 1995. Alendronate distributed on bone surfaces inhibits osteoclastic bone resorption in vitro and in experimental hypercalcemia models. Bone 16 : 235 245.
112. Sato, M. & W. Grasser. 1990. Effects of bisphosphonates on isolated rat osteoclasts as examined by reflected light microscopy. J. Bone Miner. Res. 5 : 31 40.
113. Niskikawa, M., T. Akatsu, Y. Katayama, et al. 1996. Bisphosphonates act on osteoblastic cells and inhibit osteoclast formation in mouse marrow cultures. Bone 18 : 9 14.
114. Yu, X., J. Scholler & N.T. Foged. 1996. Interaction between effects of parathyroid hormone and bisphosphonate on regulation of osteoclast activity by the osteoblast-like cell line UMR-106. Bone 19 : 339 345.
115. Sahni, M., H. Guenther, H. Fleisch, et al. 1993. Bisphosphonates act on rat bone resorption through the mediation of osteoblasts. J. Clin. Invest. 91 : 2004 2011.
116. Vitte, C., H. Fleisch & H.L. Guenther. 1996. Bisphosphonates induce osteoblasts to secrete an inhibitor of osteoclast-mediated resorption. Endocrinology 137 : 2324 2333.
117. Ito, M., M. Chokki, Y. Ogino, et al. 1998. Comparison of the cytotoxic effects of bisphosphnates in vitro and in vivo. Calcif. Tissue Int. 63 : 143 147.
118. Breuil, V., F. Cosman, L. Stein, et al. 1998. Human osteoclast formation and activity in vitro: effects of alendronate. J. Bone Miner. Res. 13 : 1721 1729.
119. Hughes, D.E., K.R. Wright, H.L. Uy, et al. 1995. Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. J. Bone Miner. Res. 10 : 1478 1487.
120. Selander, K.S., J. Mönkkönen, E.K. Karhukorpi, et al. 1996. Characteristics of clodronate-induced apoptosis in osteoclasts and macrophages. Mol. Pharmacol. 50 : 1127 1138.
121. Rogers, M.J., K.M. Chilton, F. Coxon, et al. 1996. Bisphosphonates induce apoptosis in mouse macrophage-like cells by a nitric-oxide-independent mechanism. J. Bone Miner. Res. 11 : 1482 1491.
122. Coxon, F.P., H.L. Benford, R.G.G. Russell, et al. 1998. Protein synthesis is required for caspase activation and induction of apoptosis by bisphosphonate drugs. Mol. Pharmacol. 54 : 631 638.
123. Shipman, C.M., M.J. Rogers, J.F. Apperley, et al. 1997. Bisphosphonates induce apoptosis in human myeloma cells; a novel anti-tumour activity. Br. J. Haematol. 98 : 665 672.
124. Shipman, C.M., P.I. Croucher, R.G.G. Russell, et al. 1998. The bisphosphonate incadronate (YM175) causes apoptosis of human myeloma cells in vitro by inhibiting the mevalonate pathway. Cancer Res. 58 : 5294 5297.
125. David, P., H. Nguyen, A. Barbier, et al. 1996. The bisphosphonate tiludronate is a potent inhibitor of the osteoclast vacuolar H+ ATPase. J. Bone Miner. Res. 11 : 1498 1507.
126. Carano, A., S.A. Teitelbaum, J.D. Konsek, et al. 1990. Bisphosphonates directly inhibit the bone resorption activity of isolated avian osteoclasts in vitro. J. Clin. Invest. 85 : 456 461.
127. Zimolo, Z., G. Wesolowski & G.A. Rodan. 1995. Acid extrusion is induced by osteoclast attachment to bone. J. Clin. Invest. 96 : 2277 2283.
128. Felix, R., R.G.G. Russell & H. Fleisch. 1976. The effect of several diphosphonates on acid phosphohydrolases and other lysosomal enzymes. Biochim. Biophys. Acta 429 : 429 438.
129. Lerner, U.H. & A. Larsson. 1987. Effects of four bisphosphonates on bone resorption, lysosomal enzyme release, protein synthesis and mitotic activities in mouse calvarial bones in vitro. Bone 8 : 179 189.
130. Sato, M., W. Grasser, N. Endo, et al. 1991. Bisphosphonate action. Alendronate localisation in rat bone and effects on osteoclast ultrastructure. J. Clin. Invest. 88 : 2095 2105.
131. Murakami, H., N. Takahashi, T. Sasaki, et al. 1995. A possible mechanism of the specific action of bisphosphonates on osteoclasts: tiludronate preferentially affects polarized osteoclasts having ruffled borders. Bone 17 : 137 144.
132. Schmidt, A., S.J. Rutledge, N. Endo, et al. 1995. Alendronate inhibition of protein tyrosine phosphatase activity. Proc. Natl. Acad. Sci. USA 93 : 3068 3073.
133. Endo, N., S.J. Rutledge, E.E. Opas, et al. 1996. Human protein tyrosine phosphatases: alternative splicing and inhibition by bisphosphonates. J. Bone Miner. Res. 11 : 535 543.
134. Olpas, E.E., S.J. Rutledge, E. Golub, et al. 1997. Alendronate inhibition of protein-tyrosine-phosphatase-Meg1. Biochem. Pharmacol. 54 : 721 727.
135. Murakami, H., N. Takahashi, S. Tanaka, et al. 1997. Tiludronate inhibits protein tyrosine phosphatase activity in osteoclasts. Bone 20 : 399 404.
136. Rogers, M.J. 2004. From molds and macrophages to mevalonate: a decade of progress in understanding the molecular mode of action of bisphosphonates [review]. Calcif. Tissue Int. 75 : 451 461.
137. Rogers, M.J., D.J. Watts, R.G.G. Russell, et al. 1994. Inhibitory effects of bisphosphonates on growth of amoebae of the cellular slime mould Dictyostelium discoideum. J. Bone Miner. Res. 9 : 1029 1039.
138. Rogers, M.J., X. Xiong, R.J. Brown, et al. 1995. Structure-activity relationships of new heterocycle-containing bisphosphonates as inhibitors of bone resorption and as inhibitors of growth of Dictyostelium discoideum amoebae. Mol. Pharmacol. 47 : 398 402.
139. Rogers, M.J., X. Ji, R.G.G. Russell, et al. 1994. Incorporation of bisphosphonates into adenine nucleotides by amoebae of the cellular slime mould Dictyostelium discoideum. Biochem. J. 303 : 303 311.
140. Rogers, M., R.G.G. Russell, G.M. Blackburn, et al. 1992. Metabolism of halogenated bisphosphonates by the cellular slime mould Dictyostelium discoideum. Biochem. Biophys. Res. Commun. 189 : 414 423.
141. Rogers, M.J., R.J. Brown, V. Hodkin, et al. 1996. Bisphosphonates are incorporated into adenine nucleotides by human aminoacyl-tRNA synthetase enzymes. Biochem. Biophys. Res. Commun. 224 : 863 869.
142. Pelorgeas, S., J.P. Martin & M. Satre. 1992. Cytotoxicity of dichloromethane diphosphonate and of 1-hydroxyethane-1,1-diphosphonate in the amoebae of the slime mould Dictyostelium discoideum. Biochem. Pharmacol. 44 : 2157 2163.
143. Frith, J.C., J. Mönkkönen, G.M. Blackburn, et al. 1996. Clodronate and liposome-encapsulated clodronate are metabolized to a toxic ATP analog, adenosine 5′-(β,γ-dichloromethylene) triphosphate, by mammalian cells in vitro. J. Bone Miner. Res. 12 : 1358 1367.
144. Auriola, S., J. Frith, M.J. Rogers, et al. 1997. Identification of adenine nucleotide-containing metabolites of bisphosphonate drugs using ion-pair liquid chromatography-electrospray mass spectrometry. J. Chrom. B. 704 : 187 195.
145. Frith, J.C., J. Monkkonen, S. Auriola, et al. 2001. The molecular mechanism of action of the antiresorptive and antiinflammatory drug clodronate: evidence for the formation in vivo of a metabolite that inhibits bone resorption and causes osteoclast and macrophage apoptosis. Arthritis Rheum. 44 : 2201 2210.
146. Rogers, M.J., X. Xiong, X. Ji, et al. 1997. Inhibition of growth of Dictyostelium discoideum amoebae by bisphosphonates is dependent on cellular uptake. Pharm. Res. 14 : 625 630.
147. Lehenkari, P.P., M. Kellinsalmi, J.P. Napankangas, et al. 2002. Further insight into mechanism of action of clodronate: inhibition of mitochondrial ADP/ATP translocase by a nonhydrolyzable, adenine-containing metabolite. Mol. Pharmacol. 61 : 1255 1262.
148. Zhang, F.L. & P.J. Casey. 1996. Protein prenylation: molecular mechanisms and functional consequences. Annu. Rev. Biochem. 65 : 241 269.
149. Ridley, A.J. & A. Hall. 1992. The small GTP-binding protein Rho regulates the assembly of focal adhesions and actin stress fibers in response to growth factors. Cell 70 : 389 399.
150. Ridley, A.J., H.F. Paterson, C.L. Johnston, et al. 1992. The small GTP-binding protein, rac, regulates growth factor-induced membrane ruffling. Cell 70 : 401 410.
151. Zerial, M. & H. Stenmark. 1993. Rab GTPases in vesicular transport. Curr. Opin. Cell Biol. 5 : 613 620.
152. Zhang, D., N. Udagawa, I. Nakamura, et al. 1995. The small GTP-binding protein, Rho p21, is involved in bone resorption by regulating cytoskeletal organization in osteoclasts. J. Cell Sci. 108 : 2285 2292.
153. Marshall, C. 1993. Protein prenylation: a mediator of protein-protein interactions. Science 259 : 1865 1866.
154. Luckman, S.P., D.E. Hughes, F.P. Coxon, et al. 1998. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J. Bone Miner. Res. 13 : 581 589.
155. Luckman, S.P., F.P. Coxon, F.H. Ebetino, et al. 1998. Heterocycle-containing bisphosphonates cause apoptosis and inhibit bone resorption by preventing protein prenylation: evidence from structure-activity relationships in J774 macrophages. J. Bone Miner. Res. 13 : 1668 1678.
156. Staal, A., J.C. Frith, M.H. French, et al. 2003. The ability of statins to inhibit bone resorption is directly related to their inhibitory effect on HMG-CoA reductase activity. J. Bone Miner. Res. 18 : 88 96.
157. Fisher, J.E., M.J. Rogers, J.M. Halasy, et al. 1999. Mechanism of action of alendronate: geranylgeraniol, an intermediate of the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption and kinase activation in vitro. Proc. Natl. Acad. Sci. USA 96 : 133 138.
158. Hall, A. 1998. Rho GTPases and the actin cytoskeleton. Science 279 : 509 514.
159. Amin, D., S.A. Cornell, M.H. Perrone, et al. 1996. 1-hydroxy-3- (methylpentylamino)-propylidene-1,1-bisphosphonic acid as a potent inhibitor of squalene synthase. Drug Res. 46 : 759 762.
160. Amin, D., S.A. Cornell, S.K. Gustafson, et al. 1992. Bisphosphonates used for the treatment of bone disorders inhibit squalene synthase and cholesterol biosynthesis. J. Lipid. Res. 33 : 1657 1663.
161. van Beek, E., E. Pieterman, L. Cohen, et al. Nitrogen-containing bisphosphonates inhibit isopentenyl pyrophosphate isomerase/farnesyl pyrophosphate synthase activity with relative potencies corresponding to their antiresorptive potencies in vitro and in vivo. Biochem. Biophys. Res. Commun. 255 : 491 494.
162. Dunford, J.E., K. Thompson, F.P. Coxon, et al. 2001. Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J. Pharmacol. Exp. Ther. 296 : 235 242.
163. Ebetino, F.H., C.N. Rozé, C.E. McKenna, et al. 2005. Molecular interactions of nitrogen-containing bisphosphonates within farnesyl diphosphate synthase. J. Organomet. Chem. 690 : 2679 2687.
164. Kavanagh, K., K. Guo, J. Dunford, et al. 2006. Human Farnesyl Diphosphate Synthase (FDPS): crystal structure and molecular interactions with nitrogen-containing bisphosphonates. Proc. Natl. Acad. Sci. USA In press.
165. Martin, M.B., W. Arnold, H.T. Heath, III., et al. 1999. Nitrogen-containing bisphosphonates as carbocation transition state analogs for isoprenoid biosynthesis. Biochem. Biophys. Res. Commun. 263 : 754 758.
166. Terkeltaub, R.A. 2001. Inorganic pyrophosphate generation and disposition in pathophysiology [review]. Am. J. Physiol. Cell Physiol. 281 : C1 C11.
167. Anderson, H.C., D. Harmey, N.P. Camacho, et al. 2005. Sustained osteomalacia of long bones despite major improvement in other hypophosphatasia-related mineral deficits in tissue nonspecific alkaline phosphatase/nucleotide pyrophosphatase phosphodiesterase 1 double-deficient mice. Am. J. Pathol. 166 : 1711 1720.
168. Timms, A., Y. Zhang, R.G.G. Russell, et al. 2002. Genetic studies of disorders of calcium crystal deposition. Rheumatology (Oxford) 41 : 725 729.
169. Mumm, S., J. Jones, P. Finnegan, et al. 2001. Hypophosphatasia: molecular diagnosis of Rathbun's original case. J. Bone Miner. Res. 16 : 1724 1727.
170. Fedde, K.N., L. Blair, J. Silverstein, et al. 1999. Alkaline phosphatase knock-out mice recapitulate the metabolic and skeletal defects of infantile hypophosphatasia. J. Bone Miner. Res. 14 : 2015 2026.
171. Ruf, N., B. Uhlenberg, R. Terkeltaub, et al. 2005. The mutational spectrum of ENPP1 as arising after the analysis of 23 unrelated patients with generalized arterial calcification of infancy (GACI). Hum. Mutat. 26 : 495 496.
172. Nakamura, I., S. Ikegawa, A. Okawa, et al. 1999. Association of the human NPPS gene with ossification of the posterior longitudinal ligament of the spine (OPLL). Hum. Genet. 104 : 492 497.
173. Ho, A.M., M.D. Johnson & D.M. Kingsley. 2000. Role of the mouse ank gene in control of tissue calcification and arthritis. Science 289 : 265 270.
174. Williams, C.J., Y. Zhang, A. Timms, et al. 2002. Autosomal dominant familial calcium pyrophosphate dihydrate deposition disease is caused by mutation in the transmembrane protein ANKH. Am. J. Hum. Genet. 71 : 985 991.
175. Zhang, Y., K. Johnson, R.G. Russell, et al. 2005. Association of sporadic chondrocalcinosis with a -4-basepair G-to-A transition in the 5'-untranslated region of ANKH that promotes enhanced expression of ANKH protein and excess generation of extracellular inorganic pyrophosphate. Arthritis Rheum. 52 : 1110 1117.
176. Pendleton, A., M.D. Johnson, A. Hughes, et al. 2002. Mutations in ANKH cause chondrocalcinosis. Am. J. Hum. Genet. 71 : 933 940.
177. Reichenberger, E., V. Tiziani, S. Watanabe, et al. 2001. Autosomal dominant craniometaphyseal dysplasia is caused mutations in the transmembrane protein ANK. Am. J. Hum. Genet. 68 : 1321 1326.
178. Nuernberg, P., H. Thiele, D. Chandler, et al. 2001. Heterozygous mutations in ANKH, the human ortholog of the mouse progressive ankylosis gene, result in craniometaphyseal dysplasia. Nat. Genet. 28 : 37 41.
179. Borah, B., E.L. Ritman, T.E. Dufresne, et al. 2005. The effect of risedronate on bone mineralization as measured by micro-computed tomography with synchrotron radiation: correlation to histomorphometric indices of turnover. Bone 37 : 1 9.
180. Borah, B., T.E. Dufresne, P.A. Chmielewski, et al. 2002. Risedronate preserves trabecular architecture and increases bone strength in vertebra of ovariectomized minipigs as measured by three-dimensional microcomputed tomography. J. Bone Miner. Res. 17 : 1139 1147.
181. Borah, B., T.E. Dufresne, P.A. Chmielewski, et al. 2004. Risedronate preserves bone architecture in postmenopausal women with osteoporosis as measured by three-dimensional microcomputed tomography. Bone 34 : 736 746.
182. Lalla, S., L.A. Hothorn, N. Haag, et al. 1998. Lifelong administration of high doses of ibandronate increases bone mass and maintains bone quality of lumbar vertebrae in rats. Osteoporos. Int. 8 : 97 103.
183. Bauss, F., S. Lalla, R. Endele, et al. 2002. Effects of treatment with ibandronate on bone mass, architecture, biomechanical properties, and bone concentration of ibandronate in ovariectomized aged rats. J. Rheumatol. 29 : 2200 2208.
184. Mashiba, T., S. Mori, D.B. Burr, et al. 2005. The effects of suppressed bone remodeling by bisphosphonates on microdamage accumulation and degree of mineralization in the cortical bone of dog rib. J. Bone Miner. Metab. 23 Suppl 36 42.
185. Mashiba, T., T. Hirano, C.H. Turner, et al. 2000. Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces some biomechanical properties in dog rib. J. Bone Miner. Res. 15 : 613 620.
186. Flora, L., G.S. Hassing, G.G. Cloyd, et al. 1981. The long-term skeletal effects of EHDP in dogs. Metab. Bone Dis. Relat. Res. 3 : 289 300.
187. Odvina, C.V., J.E. Zerwekh, D.S. Rao, et al. 2005. Severely suppressed bone turnover: a potential complication of alendronate therapy. J. Clin. Endocrinol. Metab. 90 : 1294 1301.
188. Ott, S.M. 2005. Long-term safety of bisphosphonates. J. Clin. Endocrinol. Metab. 90 : 1897 1899.
189. Whyte, M.P., D. Wenkert, K.L. Clements, et al. 2003. Bisphosphonate- induced osteopetrosis. N. Engl. J. Med. 349 : 457 463.
190. Monier-Faugere, M.C., Z. Geng, E.P. Paschalis, et al. 1999. Intermittent and continuous administration of the bisphosphonate ibandronate in ovariohysterectomized beagle dogs: effects on bone morphometry and mineral properties. J. Bone Miner. Res. 14 : 1768 1778.
191. Bauss, F., R.K. Schenk, S. Hort, et al. 2004. New model for simulation of fracture repair in full-grown beagle dogs: model characterization and results from a long-term study with ibandronate. J. Pharmacol. Toxicol. Methods 50 : 25 34.
192. Little, D.G., M. McDonald, R. Bransford, et al. 2005. Manipulation of the anabolic and catabolic responses with OP-1 and zoledronic acid in a rat critical defect model. J. Bone Miner. Res. 20 : 2044 2052.
193. Bobyn, J.D., S.A. Hacking, J.J. Krygier, et al. 2005. Zoledronic acid causes enhancement of bone growth into porous implants. J. Bone Joint Surg. Br. 87 : 416 420.
194. Kurth, A.H., C. Eberhardt, S. Müller, et al. 2005. The bisphosphonate ibandronate improves implant integration in osteopenic ovariectomized rats. Bone 37 : 204 210.
195. Wilkinson, J.M., A.C. Eagleton, I. Stockley, et al. 2005. Effect of pamidronate on bone turnover and implant migration after total hip arthroplasty: a randomized trial. J. Orthop Res. 23 : 1 8.
196. Little, D.G., N.C. Smith, P.R. Williams, et al. 2003. Zoledronic acid prevents osteopenia and increases bone strength in a rabbit model of distraction osteogenesis. J. Bone Miner. Res. 18 : 1300 1307.
197. Little, D.G., R.A. Peat & A. Mcevoy. 2003. Zoledronic acid treatment results in retention of femoral head structure after traumatic osteonecrosis in young Wistar rats. J. Bone Miner. Res. 18 : 2016 2022.
198. Lai, K.A., W.J. Shen, C.Y. Yang, et al. 2005. The use of alendronate to prevent early collapse of the femoral head in patients with nontraumatic osteonecrosis. A randomized clinical study. J. Bone Joint Surg. Am. 87 : 2155 2159.
199. Little, D.G., M. McDonald, I.T. Sharpe, et al. 2005. Zoledronic acid improves femoral head sphericity in a rat model of Perthes disease. J. Orthop. Res. 23 : 862 868.
200. Nancollas, G.H., R. Tang, R.J. Phipps, et al. 2005. Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite. Bone [Epub ahead of print].
201. Plotkin, L.I., R.S. Weinstein, A.M. Parfitt, et al. 1999. Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin. J. Clin. Invest. 104 : 1363 1374.
202. Plotkin, L.I., J.I. Aguirre, S. Kousteni, et al. 2005. Bisphosphonates and estrogens inhibit osteocyte apoptosis via distinct molecular mechanisms downstream of extracellular signal-regulated kinase activation. J. Biol. Chem. 280 : 7317 7325.
203. Sauty, A., M. Pecherstorfer, I. Zimmerroth, et al. 1996. Interleukin-6 and tumor necrosis factor alpha levels after bisphosphonate treatment in vitro and in patients with malignancy. Bone 18 : 133 139.
204. Schweitzer, D.H., M. Oostendorp-van de Ruit, G. van der Pluijm, et al. 1995. Interleukin-6 and the acute phase response during treatment of patients with Paget's disease with the nitrogen-containing bisphosphonate dimethylaminohydroxypropylidene bisphosphonate. J. Bone Miner. Res. 10 : 956 962.
205. Adami, S., A.K. Bhalla, R. Dorizzi, et al. 1987. The acute-phase response after bisphosphonate administration. Calcif. Tissue Int. 41 : 326 331.
206. Sanders, J.M., S. Ghosh, J.M. Chan, et al. 2004. Quantitative structure-activity relationships for gammadelta T cell activation by bisphosphonates. J. Med. Chem. 47 : 375 384.
207. Thompson, K. & M.J. Rogers. 2004. Statins prevent bisphosphonate-induced gamma,delta-T-cell proliferation and activation in vitro. J. Bone Miner. Res. 19 : 278 288.
208. Gabelli, S.B., J.S. McLellan, A. Montalvetti, et al. 2005. Structure and mechanism of the farnesyl diphosphate synthase from Trypanosoma cruzi: implications for drug design. Proteins 62 : 80 88 [Epub ahead of print].
209. Szabo, C.M., Y. Matsumura, S. Fukura, et al. 2002. Inhibition of geranylgeranyl diphosphate synthase by bisphosphonates and diphosphates: a potential route to new bone antiresorption and antiparasitic agents. J. Med. Chem. 45 : 2185 2196.
210. Ghosh, S., J.M. Chan, C.R. Lea, et al. 2004. Effects of bisphosphonates on the growth of Entamoeba histolytica and Plasmodium species in vitro and in vivo. J. Med. Chem. 47 : 175 187.
211. Martin, M.B., J.S. Grimley, J.C. Lewis, et al. 2001. Bisphosphonates inhibit the growth of Trypanosoma brucei, Trypanosoma cruzi, Leishmania donovani, Toxoplasma gondii, and Plasmodium falciparum: a potential route to chemotherapy. J. Med. Chem. 44 : 909 916.
212. Ling, Y., G. Sahota, S. Odeh, et al. 2005. Bisphosphonate inhibitors of Toxoplasma gondi growth: in vitro, QSAR, and in vivo investigations. J. Med. Chem. 48 : 3130 3140.
213. Moreno, B., B.N. Bailey, S. Luo, et al. 2001. (31)P NMR of apicomplexans and the effects of risedronate on Cryptosporidium parvum growth. Biochem. Biophys. Res. Commun. 284 : 632 637.
214. Rodriguez, N., B.N. Bailey, M.B. Martin, et al. 2002. Radical cure of experimental cutaneous leishmaniasis by the bisphosphonate pamidronate. J. Infect. Dis. 186 : 138 140.